Results 11 to 20 of about 1,009,118 (297)

Multidrug-resistant tuberculosis [PDF]

BMC Infectious Diseases, 2008
With almost 9 million new cases each year, tuberculosis remains one of the most feared diseases on the planet. Led by the STOP-TB Partnership and WHO, recent efforts to combat the disease have made considerable progress in a number of countries. However, the emergence of mutated strains of Mycobacterium tuberculosis that are resistant to the major anti-
McNerney Ruth, Zager Ellen M
openaire   +6 more sources

Multidrug resistant Acinetobacter

Journal of Global Infectious Diseases, 2010
Emergence and spread of Acinetobacter species, resistant to most of the available antimicrobial agents, is an area of great concern. It is now being frequently associated with healthcare associated infections.
Vikas Manchanda, Sinha Sanchaita, N P Singh   +2 more
doaj   +3 more sources

Multidrug Resistance

Annals of Medicine, 1991
Resistance of malignant cells to cytotoxic agents is often a limiting factor to successful chemotherapy. The classical multidrug resistance is characterised by overexpression of a membrane protein, P-glycoprotein, which acts like a drug extruding pump reducing accumulation of cytotoxic agents inside malignant cells, thereby preventing their function ...
M I, Tiirikainen, T, Krusius
openaire   +4 more sources

Multidrug resistance associated proteins in multidrug resistance [PDF]

Chinese Journal of Cancer, 2012
Multidrug resistance proteins (MRPs) are members of the C family of a group of proteins named ATP-binding cassette (ABC) transporters. These ABC transporters together form the largest branch of proteins within the human body. The MRP family comprises of 13 members, of which MRP1 to MRP9 are the major transporters indicated to cause multidrug resistance
Sodani, Kamlesh, Patel, Atish, Kathawala, Rishil J., Chen, Zhe-Sheng   +3 more
openaire   +2 more sources

Multidrug-resistant tuberculosis [PDF]

The Lancet, 2019
The ideal number of drugs needed and treatment duration are crucial issues in the management of multidrug-resistant tuberculosis (MDR-TB). Thus, we read with interest the Article by the Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017,1 the results of which support our proposal,2 from 2015, to classify anti ...
Caminero, José A ., García-Basteiro, Alberto L., Rendon, Adrian   +2 more
  +11 more sources

Programmatically selected multidrug-resistant strains drive the emergence of extensively drug-resistant tuberculosis in South Africa [PDF]

, 2013
South Africa shows one of the highest global burdens of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). Since 2002, MDR-TB in South Africa has been treated by a standardized combination therapy, which until 2010 included
Pillay, Manormoney, van Helden, Paul D., Nicolaas C. Gey van Pittius (173264), Paul D. van Helden (33594), Marlein E Bosman, Gagneux, Sebastien, Thomas C Victor, Manormoney Pillay (257769), Nicolaas C Gey van Pittius, Borna Müller (173253), Hayes, Cindy, Streicher, Elizabeth M., Andre Trollip (449922), Robin M Warren, Elizabeth M Streicher, Trollip, Andre, Violet N. Chihota (143307), Warren, Robin M., Bosman, Marlein E., Müller, Borna, Violet N Chihota, Cindy Hayes, Marisa Klopper (398815), Cindy Hayes (449923), Elizabeth M. Streicher (439727), Borna Müller, Paul D van Helden, Marlein E. Bosman (449924), Klopper, Marisa, Gerrit Coetzee, Sebastien Gagneux (149824), Chihota, Violet N., Andre Trollip, Marisa Klopper, Sebastien Gagneux, Gerrit Coetzee (296078), Victor, Thomas C., Manormoney Pillay, Coetzee, Gerrit, Gey van Pittius, Nicolaas C., Robin M. Warren (33593), Thomas C. Victor (185348)   +41 more
core   +2 more sources

Diagnosis and Interim Treatment Outcomes from the First Cohort of Multidrug-Resistant Tuberculosis Patients in Tanzania. [PDF]

, 2013
Kibong'oto National Tuberculosis Hospital (KNTH), Kilimanjaro, Tanzania. Characterize the diagnostic process and interim treatment outcomes from patients treated for multidrug-resistant tuberculosis (MDR-TB) in Tanzania.
Kumburu Happiness H., Ndusilo, N.D., Boeree, M.J., Kibiki, Gibson S, Mpagama Stellah G., Kumburu, Happiness H, Houpt, Eric R, Heysell, Scott K, Eric R Houpt, Boeree Martin J., Kisonga, Riziki M, Kibiki, G.S., Nora D Ndusilo, Jean Gratz, Ndusilo Nora D., Riziki M Kisonga, Boeree, Martin J, Lekule Isack A., Stellah G Mpagama, Martin J Boeree, Heysell, S.K., Kisonga Riziki M., Mpagama, Stellah G, Ndusilo, Nora D, Kumburu, H.H., Scott K Heysell, Lekule, Isack A, Gratz, J., Kisonga, R.M., Gratz, Jean, Kibiki Gibson S., Houpt, E.R., Gibson S Kibiki, Heysell Scott K., Mpagama, S.G., Lekule, I.A., Houpt Eric R., Isack A Lekule, Gratz Jean, Happiness H Kumburu   +39 more
core   +2 more sources

Multidrug resistant tuberculosis [PDF]

BMJ, 2015
#### The bottom line Tuberculosis remains a major cause of morbidity and mortality globally, with an estimated nine million people developing the disease and 1.5 million deaths in 2013; equating to 4100 deaths a day.1 Nevertheless, considerable gains have been made in international tuberculosis control; incidence rates are decreasing (albeit slowly ...
Millard, James, Ugarte-Gil, Cesar, Moore, David AJ   +2 more
openaire   +2 more sources

Explaining risk factors for drug-resistant tuberculosis in England and Wales: contribution of primary and secondary drug resistance [PDF]

, 2004
Drug-resistant tuberculosis can be transmitted (primary) or develop during the course of treatment (secondary). We investigated risk factors for each type of resistance.
Glynn, JR, Story, A, Hayward, AC, Watson, JM, Conaty, SJ, Drobniewski, FA   +5 more
core   +1 more source

Multidrug resistance in cancer [PDF]

BMJ, 1994
Malignant neoplasms vary in their response to cytotoxic drugs: some are sensitive, others resistant. Understanding of the biochemical basis of this resistance might lead to the development of markers that would correlate with the clinical response to the drugs - or even lead to ways of overcoming the resistance.
D R, Ferry, D J, Kerr
openaire   +2 more sources